Hainan Yuanying

Hainan Yuanying Biotechnology is a Chinese biopharmaceutical company specializing in the development of T-cell receptor-engineered T-cell (TCR-T) therapies for solid tumors. The company utilizes a proprietary platform for high-throughput TCR screening and affinity maturation to identify potent candidates targeting tumor-specific antigens. Its lead program, YYB-101, targets the NY-ESO-1 antigen and is currently being evaluated in clinical trials for indications such as synovial sarcoma. Based in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, the company benefits from regional policies that facilitate the clinical translation of innovative cell therapies. Yuanying Biotech's pipeline also includes preclinical programs targeting MAGE-A3 and PRAME. The company is supported by leading venture capital firms and maintains strong research ties with academic institutions in Beijing.